Teladoc Health Inc’s filing revealed that its Officer Vandervoort Adam C acquired Company’s shares for reported $42833.0 on Dec 02 ’25. In the deal valued at $7.49 per share,5,720 shares were bought.
Then, Nueno Carlos bought 3,897 shares, generating $29,182 in total proceeds.
Before that, Bliss Kelly bought 4,582 shares. Teladoc Health Inc shares valued at $34,311 were divested by the Officer at a price of $7.49 per share.
BMO Capital Markets initiated its Teladoc Health Inc [TDOC] rating to a Market perform in a research note published on November 13, 2025; the price target was $8. A number of analysts have revised their coverage, including Mizuho’s analysts, who began to cover the stock in late July with a ‘”a Neutral”‘ rating. Goldman began covering TDOC with “Buy” recommendation on November 15, 2024. Jefferies maintained its rating on September 17, 2024. It rated TDOC as “a Hold”.
Price Performance Review of TDOC
On Tuesday, Teladoc Health Inc [NYSE:TDOC] saw its stock jump 0.81% to $7.5. Over the last five days, the stock has gained 3.45%. Teladoc Health Inc shares have fallen nearly -34.38% since the year began. Nevertheless, the stocks have fallen -17.49% over the past one year. While a 52-week high of $15.21 was reached on 02/14/25, a 52-week low of $6.35 was recorded on 04/21/25.
Levels Of Support And Resistance For TDOC Stock
The 24-hour chart illustrates a support level at 7.41, which if violated will result in even more drops to 7.31. On the upside, there is a resistance level at 7.59. A further resistance level may holdings at 7.68.
How much short interest is there in Teladoc Health Inc?
A steep rise in short interest was recorded in Teladoc Health Inc stocks on 2025-11-14, growing by 1.49 million shares to a total of 26.42 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 24.93 million shares. There was a rise of 5.63%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on February 29, 2024 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $22 price target.
